Company attributes
Other attributes
PrimeVax Immuno-Oncology is a biotechnology company developing one-time one-week cancer treatments that is headquartered in Orange, California and was founded in 2015 by Boris Minev and Santosh Kesari.
PrimeVax Immuno-Oncology is a interested in creating treatments for cancer that utilize the entire body and personalized neo-antigens. The company worked with the combination of the dengue fever virus and autologous dendritic cells in order to create and induce a strong immune response with personalized tumor targeting. This process is part of their one-time, one-week cancer treatment.
The dengue virus is used to activate the body's natural immune functions, and the strain that is used has a zero mortality rate. The strain has also been shown to have a tolerable event profile. The autologous dendritic cells are used to direct the activated immune system to attack the patient's tumors. They are derived from the patient's native white blood cells and tumor cells to teach the T-cells the antigenic information regarding the patient's own tumors.
